BIOERODIBLE SILICON-BASED DELIVERY VEHICLES FOR DELIVERY OF THERAPEUTIC AGENTS
First Claim
Patent Images
1. A sustained release drug delivery composition comprising:
- a porous carrier material comprising a silicon-based compound; and
at least one therapeutic agent associated with the carrier material, wherein the at least one therapeutic agent includes adrenocorticotropic hormone (ACTH) or an analog thereof.
6 Assignments
0 Petitions
Accused Products
Abstract
This invention discloses bioerodible delivery compositions for delivering peptide therapeutic agents. The delivery compositions comprise a porous silicon-based carrier material loaded with the therapeutic agent. The delivery compositions may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The delivery compositions may be used for treating or preventing conditions of a patient such as chronic diseases.
-
Citations
21 Claims
-
1. A sustained release drug delivery composition comprising:
-
a porous carrier material comprising a silicon-based compound; and at least one therapeutic agent associated with the carrier material, wherein the at least one therapeutic agent includes adrenocorticotropic hormone (ACTH) or an analog thereof. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 14, 15, 16, 17, 18, 19)
-
-
12. (canceled)
-
20. A sustained release drug delivery composition, comprising a porous silicon-based carrier material and a therapeutic agent disposed in pores of the carrier material, wherein:
-
the average pore size of the carrier material is about 1 nm to about 10 nm; the therapeutic agent is adrenocorticotropic hormone or an analog thereof; the therapeutic agent has a molecular weight of about 2,000 amu to about 5,000 amu; and the composition is configured to release the therapeutic agent over the course of about one month to about one year. - View Dependent Claims (21)
-
Specification